Drug Profile

Research programme: kidney disease therapeutics - Bayer/Evotec SE

Alternative Names: BAYxxx

Latest Information Update: 28 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer; Evotec AG
Developer Bayer; Evotec SE
Class Urologics
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Endometriosis
No development reported Kidney disorders

Most Recent Events

28 Nov 2024 No recent reports of development identified for preclinical development in Kidney-disorders in Germany
28 Nov 2024 No recent reports of development identified for preclinical development in Kidney-disorders in USA
20 Jan 2022 Preclinical trials in Endometriosis in Germany (unspecified route) (Evotec pipeline, January 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com